A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorTORL Biotherapeutics, LLC
About this trial
A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL
Eligibility criteria
Qualifiers
Confirmed B-NHL, including but not limited to de novo DLBCL; FL, Grades 1 to 3A; MCL; transformed lymphoma (tFL, RT) and FL Grade 3B; MZL and MALT.
Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.
At least 1 measurable lesion per Lugano criteria.
Tumor tissue is available.
Disqualifiers
T-cell lymphoma
CLL or SL
Burkitt lymphoma and high-grade B-cell lymphoma
CNS involvement
Trial design
Treatments tested in this trial
- TORL-5-700
- TORL-5-700 at MTD/RP2D
- TORL-5-700 at MTD/RP2D in combination with another agent
Treatment groups
155 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov